110 related articles for article (PubMed ID: 11800027)
1. Phase I clinical and pharmacokinetic trial of irofulven.
Thomas JP; Arzoomanian R; Alberti D; Feierabend C; Binger K; Tutsch KD; Steele T; Marnocha R; Smith C; Smith S; MacDonald J; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2001 Dec; 48(6):467-72. PubMed ID: 11800027
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Giles F; Cortes J; Garcia-Manero G; Kornblau S; Estey E; Kwari M; Murgo A; Kantarjian H
Invest New Drugs; 2001; 19(1):13-20. PubMed ID: 11291829
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Alexandre J; Raymond E; Kaci MO; Brain EC; Lokiec F; Kahatt C; Faivre S; Yovine A; Goldwasser F; Smith SL; MacDonald JR; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 May; 10(10):3377-85. PubMed ID: 15161692
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W; Faivre S; Chieze S; Alexandre J; Lokiec F; Goldwasser F; Raymond E; Kahatt C; Taamma A; Weems G; MacDonald JR; Misset JL; Cvitkovic E
Invest New Drugs; 2006 Jul; 24(4):311-9. PubMed ID: 16683074
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.
Sherman CA; Herndon JE; Watson DM; Green MR;
Lung Cancer; 2004 Sep; 45(3):387-92. PubMed ID: 15301880
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.
Dowell JE; Johnson DH; Rogers JS; Shyr Y; McCullough N; Krozely P; DeVore RF
Invest New Drugs; 2001; 19(1):85-8. PubMed ID: 11291837
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
Seiden MV; Gordon AN; Bodurka DC; Matulonis UA; Penson RT; Reed E; Alberts DS; Weems G; Cullen M; McGuire WP
Gynecol Oncol; 2006 Apr; 101(1):55-61. PubMed ID: 16260029
[TBL] [Abstract][Full Text] [Related]
11. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.
Amato RJ; Perez C; Pagliaro L
Invest New Drugs; 2002 Nov; 20(4):413-7. PubMed ID: 12448659
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
[TBL] [Abstract][Full Text] [Related]
13. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Schilder RJ; Blessing JA; Pearl ML; Rose PG
Invest New Drugs; 2004 Aug; 22(3):343-9. PubMed ID: 15122083
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
[TBL] [Abstract][Full Text] [Related]
17. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma.
Berg WJ; Schwartz L; Yu R; Mazumdar M; Motzer RJ
Invest New Drugs; 2001; 19(4):317-20. PubMed ID: 11561691
[TBL] [Abstract][Full Text] [Related]
19. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.
Raymond E; Kahatt C; Rigolet MH; Sutherland W; Lokiec F; Alexandre J; Tombal B; Elman M; Lee MS; MacDonald JR; Cullen M; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 Nov; 10(22):7566-74. PubMed ID: 15569987
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
